We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00563095
First Posted: November 26, 2007
Last Update Posted: July 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Schering-Plough
Information provided by:
Hospital Authority, Hong Kong
November 21, 2007
November 26, 2007
July 7, 2010
March 2004
Not Provided
regression of tumour size [ Time Frame: assessment every 6 months ]
Same as current
Complete list of historical versions of study NCT00563095 on ClinicalTrials.gov Archive Site
side effects [ Time Frame: every treatment given every 8 - 12 weeks ]
Same as current
Not Provided
Not Provided
 
A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer
A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma

Primary: To compare the efficacy of TACE and TAIE.

Secondary: To compare the side effects of TACE and TAIE.

The outcome measurements include survival benefit and tumour regression induced by the two therapies.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Carcinoma, Hepatocellular
  • Procedure: Transcatheter Arterial Chemoembolization (TACE)
  • Procedure: Transcatheter Arterial Pegylated Interferon Embolization (TAIE)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
December 2008
Not Provided

Inclusion Criteria:

  • Confirmed hepatocellular carcinoma not suitable for surgery

Exclusion Criteria:

  • Portal vein thrombosis
  • Severe arteriovenous shunt
  • Bilirubin level > 50 umol/mL
  • Prothrombin time > 5 seconds
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT00563095
EC 1942-02
HARECCTR0500039
Not Provided
Not Provided
Not Provided
Not Provided
Hospital Authority, Hong Kong
Schering-Plough
Principal Investigator: Man Fung Yuen, Prof Department of Medicine, Queen Mary Hospital/ The University of Hong Kong
Hospital Authority, Hong Kong
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP